View:
Download DOC
Download PDF
Download XLS
Download XBRL
8-K
false000134891100013489112024-10-032024-10-03

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 03, 2024

 

 

KALVISTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36830

20-0915291

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

55 Cambridge Parkway

Suite 901E

 

Cambridge, Massachusetts

 

02142

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 999-0075

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

KALV

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On October 3, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (“Annual Meeting”) and the following proposals were adopted:

1. Election of two Class III directors, William Fairey and Nancy Stuart (each to serve a three-year term, which will expire at the 2027 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified):

Nominees

Shares

For

Shares Against

Shares Abstaining

Broker Non-Votes

William Fairey

30,169,349

872,398

33,171

8,328,823

Nancy Stuart

19,324,277

11,717,484

33,157

8,328,823

2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2025:

Shares For

Shares Against

Shares Abstaining

Broker Non-Votes

39,323,443

46,858

33,440

0

3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers:

Shares For

Shares Against

Shares Abstaining

Broker Non-Votes

26,578,805

4,459,363

36,750

8,328,823

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

KALVISTA PHARMACEUTICALS, INC.

 

 

 

 

Date:

October 4, 2024

By:

/s/ Benjamin L. Palleiko

 

 

 

Benjamin L. Palleiko
Chief Executive Officer